researchpharmaceut lundbeck vyepti eptinezumab approv introduc anticip competitor cgrp market read agn/ teva see deep dive sentiment indic neutral weekend lundbeck announc iv-administ anti-cgrp therapi vyepti eptinezumab approv fda prevent treatment migrain adult coincid pdufa commerci launch expect april point vyepti becom fourth prevent cgrp therapi market along aimovig ajovi emgal one administ intraven base recent survey neurologist expect vyepti carv nich market physician anticip market share otherwis materi affect outlook teva ajovi expect take share post autoinjector launch agn/ botox expect larg hold share full survey result see report pharmaceut new cgrp survey deep dive increment posit agn/ less bearish teva rais pt compani nameexchangetickerratingrisk qualifierpric targetcurrencypricepric dateabbvi incnys ussector performnot feb etergan public limit companynyseagn ussector performnot feb etteva pharmaceuticalnyseteva ussector performnot feb et capit market llc randal stanicki capit market llc ashley ryu daniel busbi edwin delfin click conflict interest disclosur relat abbvi inc ergan public limit compani teva pharmaceut randal stanicki disclosur also avail send written request capit market research publish bay street royal bank plaza floor south tower toronto ontario email right reserv materi may publish broadcast rewritten redistribut form pleas click legal restrict term use applic site use site signifi agreement term use
